טוען...
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives
Immune-checkpoint inhibitors have become valuable therapies in the treatment of patients with non-small-cell lung cancer (NSCLC). Recent clinical trials have shown promising results with regard to efficacy and toxicity profiles of these agents compared to cytotoxic chemotherapy. Nivolumab was one of...
שמור ב:
| הוצא לאור ב: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5533488/ https://ncbi.nlm.nih.gov/pubmed/28769573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S97903 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|